Click for best price
RNA Interference RNAi Drug Delivery Market Size, Share 2022
Market Analysis and Insights: Global RNA Interference RNAi Drug Delivery Market
The global RNA Interference RNAi Drug Delivery market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global RNA Interference RNAi Drug Delivery market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global RNA Interference RNAi Drug Delivery market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global RNA Interference RNAi Drug Delivery market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global RNA Interference RNAi Drug Delivery market.
Global RNA Interference RNAi Drug Delivery Scope and Market Size
RNA Interference (RNAi) Drug Delivery market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global RNA Interference (RNAi) Drug Delivery market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the RNA Interference (RNAi) Drug Delivery market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Segment by Application
- Infectious Diseases
- Cardiology
- Oncology
- Neurology
- Ophthalmology
- Metabolic Disorders
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- U.A.E
By Company
- Metabolic disorders
- Alnylam Pharmaceuticals Inc
- Merck & Co. Inc
- Access Pharmaceuticals Inc
- Dicerna Pharmaceuticals Inc
- Calondo Pharmaceuticals Inc
- Marina Biotech Inc
- RXi Pharmaceuticals Corp
- Quark Pharmaceuticals Inc
- Silence Therapeutics plc
- Tacere Therapeutics Inc
- PhaseRx Inc
- Sirnaomics Inc
- Traversa Therapeutics Inc
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes RNA Interference RNAi Drug Delivery product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of RNA Interference RNAi Drug Delivery, with price, sales, revenue, and global market share of RNA Interference RNAi Drug Delivery from 2019 to 2022.
Chapter 3, the RNA Interference RNAi Drug Delivery competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the RNA Interference RNAi Drug Delivery breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the RNA Interference RNAi Drug Delivery market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of RNA Interference RNAi Drug Delivery.
Chapter 13, 14, and 15, to describe RNA Interference RNAi Drug Delivery sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 RNA Interference RNAi Drug Delivery Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States RNA Interference (RNAi) Drug Delivery Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
106 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 RNA Interference (RNAi) Drug Delivery Product Introduction
1.2 Global RNA Interference (RNAi) Drug Delivery Outlook 2017 VS 2022 VS 2028
1.2.1 Global RNA Interference (RNAi) Drug Delivery Sales in US$ Million for the Year 2017-2028
1.2.2 Global RNA Interference (RNAi) Drug Delivery Sales in Volume for the Year 2017-2028
1.3 United States RNA Interference (RNAi) Drug Delivery Outlook 2017 VS 2022 VS 2028
1.3.1 United States RNA Interference (RNAi) Drug Delivery Sales in US$ Million for the Year 2017-2028
1.3.2 United States RNA Interference (RNAi) Drug Delivery Sales in Volume for the Year 2017-2028
1.4 RNA Interference (RNAi) Drug Delivery Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States RNA Interference (RNAi) Drug Delivery in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of RNA Interference (RNAi) Drug Delivery Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 RNA Interference (RNAi) Drug Delivery Market Dynamics
1.5.1 RNA Interference (RNAi) Drug Delivery Industry Trends
1.5.2 RNA Interference (RNAi) Drug Delivery Market Drivers
1.5.3 RNA Interference (RNAi) Drug Delivery Market Challenges
1.5.4 RNA Interference (RNAi) Drug Delivery Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 RNA Interference (RNAi) Drug Delivery Market Segment by Type
2.1.1 Nanoparticle Drug Delivery Technology
2.1.2 Pulmonary Drug Delivery Technology
2.1.3 Nucleic Acid Drug Delivery Technology
2.1.4 Aptamer Drug Delivery Technology
2.2 Global RNA Interference (RNAi) Drug Delivery Market Size by Type
2.2.1 Global RNA Interference (RNAi) Drug Delivery Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global RNA Interference (RNAi) Drug Delivery Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global RNA Interference (RNAi) Drug Delivery Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States RNA Interference (RNAi) Drug Delivery Market Size by Type
2.3.1 United States RNA Interference (RNAi) Drug Delivery Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States RNA Interference (RNAi) Drug Delivery Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States RNA Interference (RNAi) Drug Delivery Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 RNA Interference (RNAi) Drug Delivery Market Segment by Application
3.1.1 Infectious Diseases
3.1.2 Cardiology
3.1.3 Oncology
3.1.4 Neurology
3.1.5 Ophthalmology
3.1.6 Metabolic Disorders
3.2 Global RNA Interference (RNAi) Drug Delivery Market Size by Application
3.2.1 Global RNA Interference (RNAi) Drug Delivery Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global RNA Interference (RNAi) Drug Delivery Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global RNA Interference (RNAi) Drug Delivery Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States RNA Interference (RNAi) Drug Delivery Market Size by Application
3.3.1 United States RNA Interference (RNAi) Drug Delivery Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States RNA Interference (RNAi) Drug Delivery Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States RNA Interference (RNAi) Drug Delivery Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global RNA Interference (RNAi) Drug Delivery Competitor Landscape by Company
4.1 Global RNA Interference (RNAi) Drug Delivery Market Size by Company
4.1.1 Top Global RNA Interference (RNAi) Drug Delivery Manufacturers Ranked by Revenue (2021)
4.1.2 Global RNA Interference (RNAi) Drug Delivery Revenue by Manufacturer (2017-2022)
4.1.3 Global RNA Interference (RNAi) Drug Delivery Sales by Manufacturer (2017-2022)
4.1.4 Global RNA Interference (RNAi) Drug Delivery Price by Manufacturer (2017-2022)
4.2 Global RNA Interference (RNAi) Drug Delivery Concentration Ratio (CR)
4.2.1 RNA Interference (RNAi) Drug Delivery Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of RNA Interference (RNAi) Drug Delivery in 2021
4.2.3 Global RNA Interference (RNAi) Drug Delivery Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global RNA Interference (RNAi) Drug Delivery Manufacturing Base Distribution, Product Type
4.3.1 Global RNA Interference (RNAi) Drug Delivery Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers RNA Interference (RNAi) Drug Delivery Product Type
4.3.3 Date of International Manufacturers Enter into RNA Interference (RNAi) Drug Delivery Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States RNA Interference (RNAi) Drug Delivery Market Size by Company
4.5.1 Top RNA Interference (RNAi) Drug Delivery Players in United States, Ranked by Revenue (2021)
4.5.2 United States RNA Interference (RNAi) Drug Delivery Revenue by Players (2020, 2021 & 2022)
4.5.3 United States RNA Interference (RNAi) Drug Delivery Sales by Players (2020, 2021 & 2022)
5 Global RNA Interference (RNAi) Drug Delivery Market Size by Region
5.1 Global RNA Interference (RNAi) Drug Delivery Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global RNA Interference (RNAi) Drug Delivery Market Size in Volume by Region (2017-2028)
5.2.1 Global RNA Interference (RNAi) Drug Delivery Sales in Volume by Region: 2017-2022
5.2.2 Global RNA Interference (RNAi) Drug Delivery Sales in Volume Forecast by Region (2023-2028)
5.3 Global RNA Interference (RNAi) Drug Delivery Market Size in Value by Region (2017-2028)
5.3.1 Global RNA Interference (RNAi) Drug Delivery Sales in Value by Region: 2017-2022
5.3.2 Global RNA Interference (RNAi) Drug Delivery Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2017-2028
6.1.2 North America RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2017-2028
6.3.2 Europe RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2017-2028
6.4.2 Latin America RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Metabolic disorders
7.1.1 Metabolic disorders Corporation Information
7.1.2 Metabolic disorders Description and Business Overview
7.1.3 Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Metabolic disorders RNA Interference (RNAi) Drug Delivery Products Offered
7.1.5 Metabolic disorders Recent Development
7.2 Alnylam Pharmaceuticals Inc
7.2.1 Alnylam Pharmaceuticals Inc Corporation Information
7.2.2 Alnylam Pharmaceuticals Inc Description and Business Overview
7.2.3 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
7.2.5 Alnylam Pharmaceuticals Inc Recent Development
7.3 Merck & Co. Inc
7.3.1 Merck & Co. Inc Corporation Information
7.3.2 Merck & Co. Inc Description and Business Overview
7.3.3 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Products Offered
7.3.5 Merck & Co. Inc Recent Development
7.4 Access Pharmaceuticals Inc
7.4.1 Access Pharmaceuticals Inc Corporation Information
7.4.2 Access Pharmaceuticals Inc Description and Business Overview
7.4.3 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
7.4.5 Access Pharmaceuticals Inc Recent Development
7.5 Dicerna Pharmaceuticals Inc
7.5.1 Dicerna Pharmaceuticals Inc Corporation Information
7.5.2 Dicerna Pharmaceuticals Inc Description and Business Overview
7.5.3 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
7.5.5 Dicerna Pharmaceuticals Inc Recent Development
7.6 Calondo Pharmaceuticals Inc
7.6.1 Calondo Pharmaceuticals Inc Corporation Information
7.6.2 Calondo Pharmaceuticals Inc Description and Business Overview
7.6.3 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
7.6.5 Calondo Pharmaceuticals Inc Recent Development
7.7 Marina Biotech Inc
7.7.1 Marina Biotech Inc Corporation Information
7.7.2 Marina Biotech Inc Description and Business Overview
7.7.3 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Products Offered
7.7.5 Marina Biotech Inc Recent Development
7.8 RXi Pharmaceuticals Corp
7.8.1 RXi Pharmaceuticals Corp Corporation Information
7.8.2 RXi Pharmaceuticals Corp Description and Business Overview
7.8.3 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.8.4 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Products Offered
7.8.5 RXi Pharmaceuticals Corp Recent Development
7.9 Quark Pharmaceuticals Inc
7.9.1 Quark Pharmaceuticals Inc Corporation Information
7.9.2 Quark Pharmaceuticals Inc Description and Business Overview
7.9.3 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
7.9.5 Quark Pharmaceuticals Inc Recent Development
7.10 Silence Therapeutics plc
7.10.1 Silence Therapeutics plc Corporation Information
7.10.2 Silence Therapeutics plc Description and Business Overview
7.10.3 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Products Offered
7.10.5 Silence Therapeutics plc Recent Development
7.11 Tacere Therapeutics Inc
7.11.1 Tacere Therapeutics Inc Corporation Information
7.11.2 Tacere Therapeutics Inc Description and Business Overview
7.11.3 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Products Offered
7.11.5 Tacere Therapeutics Inc Recent Development
7.12 PhaseRx Inc
7.12.1 PhaseRx Inc Corporation Information
7.12.2 PhaseRx Inc Description and Business Overview
7.12.3 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.12.4 PhaseRx Inc Products Offered
7.12.5 PhaseRx Inc Recent Development
7.13 Sirnaomics Inc
7.13.1 Sirnaomics Inc Corporation Information
7.13.2 Sirnaomics Inc Description and Business Overview
7.13.3 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Sirnaomics Inc Products Offered
7.13.5 Sirnaomics Inc Recent Development
7.14 Traversa Therapeutics Inc
7.14.1 Traversa Therapeutics Inc Corporation Information
7.14.2 Traversa Therapeutics Inc Description and Business Overview
7.14.3 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Traversa Therapeutics Inc Products Offered
7.14.5 Traversa Therapeutics Inc Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 RNA Interference (RNAi) Drug Delivery Industry Chain Analysis
8.2 RNA Interference (RNAi) Drug Delivery Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 RNA Interference (RNAi) Drug Delivery Distributors
8.3 RNA Interference (RNAi) Drug Delivery Production Mode & Process
8.4 RNA Interference (RNAi) Drug Delivery Sales and Marketing
8.4.1 RNA Interference (RNAi) Drug Delivery Sales Channels
8.4.2 RNA Interference (RNAi) Drug Delivery Distributors
8.5 RNA Interference (RNAi) Drug Delivery Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. RNA Interference (RNAi) Drug Delivery CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. RNA Interference (RNAi) Drug Delivery Market Trends
Table 3. RNA Interference (RNAi) Drug Delivery Market Drivers
Table 4. RNA Interference (RNAi) Drug Delivery Market Challenges
Table 5. RNA Interference (RNAi) Drug Delivery Market Restraints
Table 6. Global RNA Interference (RNAi) Drug Delivery Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States RNA Interference (RNAi) Drug Delivery Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global RNA Interference (RNAi) Drug Delivery Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States RNA Interference (RNAi) Drug Delivery Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top RNA Interference (RNAi) Drug Delivery Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global RNA Interference (RNAi) Drug Delivery Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global RNA Interference (RNAi) Drug Delivery Revenue Share by Manufacturer, 2017-2022
Table 13. Global RNA Interference (RNAi) Drug Delivery Sales by Manufacturer, (K Units), 2017-2022
Table 14. Global RNA Interference (RNAi) Drug Delivery Sales Share by Manufacturer, 2017-2022
Table 15. Global RNA Interference (RNAi) Drug Delivery Price by Manufacturer (2017-2022) & (USD/Unit)
Table 16. Global RNA Interference (RNAi) Drug Delivery Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global RNA Interference (RNAi) Drug Delivery by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA Interference (RNAi) Drug Delivery as of 2021)
Table 18. Top Players of RNA Interference (RNAi) Drug Delivery in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers RNA Interference (RNAi) Drug Delivery Product Type
Table 20. Date of International Manufacturers Enter into RNA Interference (RNAi) Drug Delivery Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top RNA Interference (RNAi) Drug Delivery Players in United States Market, Ranking by Revenue (2021)
Table 23. United States RNA Interference (RNAi) Drug Delivery Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States RNA Interference (RNAi) Drug Delivery Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States RNA Interference (RNAi) Drug Delivery Sales by Players, (K Units), 2020, 2021 & 2022
Table 26. United States RNA Interference (RNAi) Drug Delivery Sales Share by Players, 2020, 2021 & 2022
Table 27. Global RNA Interference (RNAi) Drug Delivery Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global RNA Interference (RNAi) Drug Delivery Sales in Volume by Region (2017-2022) & (K Units)
Table 29. Global RNA Interference (RNAi) Drug Delivery Sales in Volume Forecast by Region (2023-2028) & (K Units)
Table 30. Global RNA Interference (RNAi) Drug Delivery Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global RNA Interference (RNAi) Drug Delivery Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2017-2028) & (K Units)
Table 33. North America RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific RNA Interference (RNAi) Drug Delivery Sales in Volume by Region (2017-2028) & (K Units)
Table 35. Asia Pacific RNA Interference (RNAi) Drug Delivery Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2017-2028) & (K Units)
Table 37. Europe RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2017-2028) & (K Units)
Table 39. Latin Americaa RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2017-2028) & (K Units)
Table 41. Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Metabolic disorders Corporation Information
Table 43. Metabolic disorders Description and Business Overview
Table 44. Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 45. Metabolic disorders RNA Interference (RNAi) Drug Delivery Product
Table 46. Metabolic disorders Recent Development
Table 47. Alnylam Pharmaceuticals Inc Corporation Information
Table 48. Alnylam Pharmaceuticals Inc Description and Business Overview
Table 49. Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 50. Alnylam Pharmaceuticals Inc Product
Table 51. Alnylam Pharmaceuticals Inc Recent Development
Table 52. Merck & Co. Inc Corporation Information
Table 53. Merck & Co. Inc Description and Business Overview
Table 54. Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 55. Merck & Co. Inc Product
Table 56. Merck & Co. Inc Recent Development
Table 57. Access Pharmaceuticals Inc Corporation Information
Table 58. Access Pharmaceuticals Inc Description and Business Overview
Table 59. Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 60. Access Pharmaceuticals Inc Product
Table 61. Access Pharmaceuticals Inc Recent Development
Table 62. Dicerna Pharmaceuticals Inc Corporation Information
Table 63. Dicerna Pharmaceuticals Inc Description and Business Overview
Table 64. Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 65. Dicerna Pharmaceuticals Inc Product
Table 66. Dicerna Pharmaceuticals Inc Recent Development
Table 67. Calondo Pharmaceuticals Inc Corporation Information
Table 68. Calondo Pharmaceuticals Inc Description and Business Overview
Table 69. Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 70. Calondo Pharmaceuticals Inc Product
Table 71. Calondo Pharmaceuticals Inc Recent Development
Table 72. Marina Biotech Inc Corporation Information
Table 73. Marina Biotech Inc Description and Business Overview
Table 74. Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 75. Marina Biotech Inc Product
Table 76. Marina Biotech Inc Recent Development
Table 77. RXi Pharmaceuticals Corp Corporation Information
Table 78. RXi Pharmaceuticals Corp Description and Business Overview
Table 79. RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 80. RXi Pharmaceuticals Corp Product
Table 81. RXi Pharmaceuticals Corp Recent Development
Table 82. Quark Pharmaceuticals Inc Corporation Information
Table 83. Quark Pharmaceuticals Inc Description and Business Overview
Table 84. Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 85. Quark Pharmaceuticals Inc Product
Table 86. Quark Pharmaceuticals Inc Recent Development
Table 87. Silence Therapeutics plc Corporation Information
Table 88. Silence Therapeutics plc Description and Business Overview
Table 89. Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 90. Silence Therapeutics plc Product
Table 91. Silence Therapeutics plc Recent Development
Table 92. Tacere Therapeutics Inc Corporation Information
Table 93. Tacere Therapeutics Inc Description and Business Overview
Table 94. Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 95. Tacere Therapeutics Inc Product
Table 96. Tacere Therapeutics Inc Recent Development
Table 97. PhaseRx Inc Corporation Information
Table 98. PhaseRx Inc Description and Business Overview
Table 99. PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 100. PhaseRx Inc Product
Table 101. PhaseRx Inc Recent Development
Table 102. Sirnaomics Inc Corporation Information
Table 103. Sirnaomics Inc Description and Business Overview
Table 104. Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 105. Sirnaomics Inc Product
Table 106. Sirnaomics Inc Recent Development
Table 107. Traversa Therapeutics Inc Corporation Information
Table 108. Traversa Therapeutics Inc Description and Business Overview
Table 109. Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 110. Traversa Therapeutics Inc Product
Table 111. Traversa Therapeutics Inc Recent Development
Table 112. Key Raw Materials Lists
Table 113. Raw Materials Key Suppliers Lists
Table 114. RNA Interference (RNAi) Drug Delivery Customers List
Table 115. RNA Interference (RNAi) Drug Delivery Distributors List
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. RNA Interference (RNAi) Drug Delivery Product Picture
Figure 2. Global RNA Interference (RNAi) Drug Delivery Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global RNA Interference (RNAi) Drug Delivery Market Size 2017-2028 (US$ Million)
Figure 4. Global RNA Interference (RNAi) Drug Delivery Sales 2017-2028 (K Units)
Figure 5. United States RNA Interference (RNAi) Drug Delivery Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States RNA Interference (RNAi) Drug Delivery Market Size 2017-2028 (US$ Million)
Figure 7. United States RNA Interference (RNAi) Drug Delivery Sales 2017-2028 (K Units)
Figure 8. United States RNA Interference (RNAi) Drug Delivery Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States RNA Interference (RNAi) Drug Delivery Market Share in Global, in Volume (K Units) 2017-2028
Figure 10. RNA Interference (RNAi) Drug Delivery Report Years Considered
Figure 11. Product Picture of Nanoparticle Drug Delivery Technology
Figure 12. Product Picture of Pulmonary Drug Delivery Technology
Figure 13. Product Picture of Nucleic Acid Drug Delivery Technology
Figure 14. Product Picture of Aptamer Drug Delivery Technology
Figure 15. Global RNA Interference (RNAi) Drug Delivery Market Share by Type in 2022 & 2028
Figure 16. Global RNA Interference (RNAi) Drug Delivery Sales in Value by Type (2017-2028) & (US$ Million)
Figure 17. Global RNA Interference (RNAi) Drug Delivery Sales Market Share in Value by Type (2017-2028)
Figure 18. Global RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2028) & (K Units)
Figure 19. Global RNA Interference (RNAi) Drug Delivery Sales Market Share in Volume by Type (2017-2028)
Figure 20. Global RNA Interference (RNAi) Drug Delivery Price by Type (2017-2028) & (USD/Unit)
Figure 21. United States RNA Interference (RNAi) Drug Delivery Market Share by Type in 2022 & 2028
Figure 22. United States RNA Interference (RNAi) Drug Delivery Sales in Value by Type (2017-2028) & (US$ Million)
Figure 23. United States RNA Interference (RNAi) Drug Delivery Sales Market Share in Value by Type (2017-2028)
Figure 24. United States RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2028) & (K Units)
Figure 25. United States RNA Interference (RNAi) Drug Delivery Sales Market Share in Volume by Type (2017-2028)
Figure 26. United States RNA Interference (RNAi) Drug Delivery Price by Type (2017-2028) & (USD/Unit)
Figure 27. Product Picture of Infectious Diseases
Figure 28. Product Picture of Cardiology
Figure 29. Product Picture of Oncology
Figure 30. Product Picture of Neurology
Figure 31. Product Picture of Ophthalmology
Figure 32. Product Picture of Metabolic Disorders
Figure 33. Global RNA Interference (RNAi) Drug Delivery Market Share by Application in 2022 & 2028
Figure 34. Global RNA Interference (RNAi) Drug Delivery Sales in Value by Application (2017-2028) & (US$ Million)
Figure 35. Global RNA Interference (RNAi) Drug Delivery Sales Market Share in Value by Application (2017-2028)
Figure 36. Global RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2028) & (K Units)
Figure 37. Global RNA Interference (RNAi) Drug Delivery Sales Market Share in Volume by Application (2017-2028)
Figure 38. Global RNA Interference (RNAi) Drug Delivery Price by Application (2017-2028) & (USD/Unit)
Figure 39. United States RNA Interference (RNAi) Drug Delivery Market Share by Application in 2022 & 2028
Figure 40. United States RNA Interference (RNAi) Drug Delivery Sales in Value by Application (2017-2028) & (US$ Million)
Figure 41. United States RNA Interference (RNAi) Drug Delivery Sales Market Share in Value by Application (2017-2028)
Figure 42. United States RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2028) & (K Units)
Figure 43. United States RNA Interference (RNAi) Drug Delivery Sales Market Share in Volume by Application (2017-2028)
Figure 44. United States RNA Interference (RNAi) Drug Delivery Price by Application (2017-2028) & (USD/Unit)
Figure 45. North America RNA Interference (RNAi) Drug Delivery Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 46. North America RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 47. U.S. RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 48. Canada RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. Europe RNA Interference (RNAi) Drug Delivery Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 50. Europe RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 51. Germany RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. France RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. U.K. RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. Italy RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. Russia RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 57. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 58. China RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Japan RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. South Korea RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. India RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Australia RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Taiwan RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Indonesia RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Thailand RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Malaysia RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Philippines RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Latin America RNA Interference (RNAi) Drug Delivery Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 69. Latin America RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 70. Mexico RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. Brazil RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. Argentina RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 74. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 75. Turkey RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 76. Saudi Arabia RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 77. U.A.E RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 78. RNA Interference (RNAi) Drug Delivery Value Chain
Figure 79. RNA Interference (RNAi) Drug Delivery Production Process
Figure 80. Channels of Distribution
Figure 81. Distributors Profiles
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed
